Literature DB >> 221515

Suppression of plasma catecholamines and flushing by clonidine in man.

S A Metz, J B Halter, D Porte, R P Robertson.   

Abstract

Administration of the anti-hypertensive agent clonidine as a single (0.5 mg) oral dose or as multiple doses (0.2-0.4 mg/day for 4 days) markedly reduced plasma catecholamines (decrement = 81 +/- 3% and 68 +/- 5%, respectively; X +/- SE, % of basal; both P less than 0.001) in normal male volunteers. Five patients with various metabolic disorders showed similar responses. The absolute decrements in plasma catecholamines correlated significantly with basal catecholamine levels (P less than 0.001). Clonidine-induced decrements in mean arterial blood pressure correlated significantly with decrements in plasma catecholamines (P less than 0.001). The clonidine effect upon catecholamine levels was reversed by phentolamine (clonidine = -68 +/- 5%; clonidine with phentolamine = -1 +/- 16%). The decrements in catecholamines induced by clonidine in normal subjects were associated with increased sensitivity to the pressor effect of infusion of exogenous norepinephrine. In an analogous fashion flushing associated with endogenous adrenergic discharge was blocked by clonidine, whereas that due to exogenous catecholamines was intensified. These data are compatible with data in experimental animals suggesting that clonidine acts at least in part by interaction with a central alpha adrenergic receptor.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 221515     DOI: 10.1210/jcem-46-1-83

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Diagnostic problems in pheochromocytoma.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

Review 2.  Flushing in (neuro)endocrinology.

Authors:  Fady Hannah-Shmouni; Constantine A Stratakis; Christian A Koch
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

3.  Differences in psychic performance with guanfacine and clonidine in normotensive subjects.

Authors:  J Kugler; R Seus; R Krauskopf; H M Brecht; A Raschig
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

4.  Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.

Authors:  D P Nicholls; J McNeill; P C O'Connor; D W Harron; W J Leahey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

5.  Blood noradrenaline and 5-HT levels in depressed women during amitriptyline or lithium treatment.

Authors:  G L Corona; M L Cucchi; G Santagostino; P Frattini; F Zerbi; L Fenoglio; F Savoldi
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  Oral glucose tolerance and insulin response after one week's clonidine treatment in hypertensive patients.

Authors:  C Barbieri; R Caldara; G Testori; V Piepoli; R Trezzi; M Romussi; C Ferrari
Journal:  Acta Diabetol Lat       Date:  1981

7.  Acute effects of alinidine on heart rate and blood pressure in healthy subjects and patients with hyperkinetic heart syndrome.

Authors:  B Stanek; W Reiterer; P Placheta; G Raberger
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Usefulness of basal catecholamine plasma levels and clonidine suppression test in the diagnosis of pheochromocytoma.

Authors:  M Mannelli; M L De Feo; M Maggi; C Pupilli; G Opocher; T Valenza; E Baldi; M Serio
Journal:  J Endocrinol Invest       Date:  1987-08       Impact factor: 4.256

9.  Clonidine-induced suppression of plasma catecholamines in states of adrenal medulla hyperfunction.

Authors:  M D Gross; B Shapiro; J C Sisson; A Zweifler
Journal:  J Endocrinol Invest       Date:  1987-08       Impact factor: 4.256

10.  Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects.

Authors:  S N Anavekar; B Jarrott; M Toscano; W J Louis
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.